

ESMO Advanced Course on NTRK Gene Fusion: a new target in precision treatment of cancer

Programme

**LYON
FRANCE**

13-14 SEPTEMBER 2019

Co-Chairs

Jean-Yves Blay, France

Frédérique Penault-Llorca, France

ESMO ADVANCED COURSE PROGRAMME

NTRK GENE FUSION: A NEW TARGET IN PRECISION TREATMENT OF CANCER

Lyon, France
13-14 September 2019

CO-CHAIRS: Jean-Yves Blay, France
Frédérique Penault-Llorca, France

SPEAKERS: Mehdi Brahmi, France
Jorge Camarero, Spain
Elise Deluche, France
Ulrik Lassen, Denmark
Caterina Marchiò, Italy
Joaquin Mateo, Spain
David Planchard, France

LEARNING OBJECTIVE

- Acquire knowledge of the TRK Family members and their roles in ontogenesis
- Understand the mechanisms of gene fusion and the different fusion partners involved
- Learn how TRK receptors are structured and how their activation impacts signal transduction
- Review the epidemiology of NTRK gene fusion in human tumours
- Understand the methodology to identify NTRK gene fusion and the challenges of testing
- Update your knowledge on the present outcome obtained with NTRK inhibitors, their toxicities and clinical management

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 13 September 2019

09:00-09:10 10'	Welcome and introduction Jean-Yves Blay, FR Frédérique Penault-Llorca, FR
09:10-10:10 60'	Session 1: Keynote lecture <i>Gene fusion in human cancer</i> Mechanisms of gene fusion, fusion partners and consequences in oncogenesis Description, structure and function of TRK and NTRK in ontogenesis Medhi Brahmi, FR
10:10-10:40 30'	Session 2 <i>Epidemiology and distribution of NTRK gene fusion in human tumours</i> Elise Deluche, FR
10:40-11:10	Coffee break
11:10-11:55 45'	Session 3 <i>Identification/testing methodologies and Challenges</i> Caterina Marchiò, IT
11:55-13:00	Lunch
13:00-13:30 30'	Session 4 <i>Detection of gene fusion within the ESMO scale of Molecular Target (ESCAT)</i> Joaquin Mateo, ES
13:30-15:00	Session 5 <i>Clinical development of NTRK inhibitors (Part 1)</i>
30'	Analysis of Regulatory agencies approval Jorge Camarero, ES
30'	Present results with Larotectinib Ulrik Lassen, DK
30'	Tolerance profile and recommendation for use David Planchard, FR
15:00-15:30	Coffee break
15:30-17:00	Session 6 <i>Clinical development of NTRK inhibitors (Part 2)</i>
45'	Multi Kinases inhibitors with NTRK as a possible target David Planchard, FR
45'	Acquired resistance to NTRK Inhibitors and development of inhibitors targeting resistance mutations Ulrik Lassen, DK
20:00	Networking Dinner

Saturday, 14 September 2019

09:00-12:30

Workshop sessions

Two parallel workshop sessions with 30 delegates in each group
(1 dedicated Workshop for Medical Oncologists & 1 dedicated Workshop for Pathologists)

Workshop 1

90'

Workshop for Medical Oncologists

Ulrik Lassen, DK

Structure:

- Presentation of 3 clinical cases by speakers (3 different NTRK tumours type)
- Discussion & Questions

Workshop 2

90'

Workshop for Pathologists

Frédérique Penault-Llorca, FR

Structure:

- Technical aspects of NTRK diagnosis technics (theoretical aspects, methods)
- Discussion & Questions

10:30-11:00

Coffee break

Workshop 1 & 2 Continuation

90'

12:30-13:00

Feedback on the workshops from each group

13:00-13:15

Conclusion and farewell

13:15-14:15

Lunch